Journal
ONCOGENE
Volume 22, Issue 42, Pages 6621-6628Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1206958
Keywords
pharmacogenomics; cancer chemotherapy; EGFR; irinotecan; thymidylate synthase
Funding
- NIGMS NIH HHS [U01GM61393] Funding Source: Medline
Ask authors/readers for more resources
Interindividual differences in the toxicity and response to anticancer therapies are currently observed for essentially all available treatment regimens. Such 'unpredictable' drug responses are particularly dangerous in the context of anticancer agents that have narrow therapeutic indices. Pharmacogenomics attempts to elucidate the inherited basis of interindividual differences in drug response, with the eventual goal of minimizing such variability through the use of 'individualized' treatments. There are several emerging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug targets that have been shown to influence the toxicity and efficacy of anticancer treatment. This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available